ClinicalTrials.gg
CompletedNCT00763607Updated Sep 10, 2022

Retrospective Study Evaluating IGF1R And p95HER2 as Prognostic Factors in Non Small Cell Lung Cancer (NSCLC)

An observational study in Non Small Cell Lung Cancer, sponsored by Armando Santoro, MD. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-09-10.

Sponsored by Armando Santoro, MD · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
454
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy — 156 open to participants now, 286 under way, 104 of them phase 3. Carcinoma, Non-Small-Cell Lung · Italy.

Enrollment
17th of 67
454 · median 200
Started
2007
with 14 others
Observational
67 of 716
37 open now
Registered
96th of 716
by date

Among the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, this one is the 17th largest by enrollment of the 67 observational ones that give a count, is one of 15 that started in 2007, is one of 67 observational ones, and was the 96th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

156 of the 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy are open now. Recruiting first, the newest first:

151 more — sign in →

All 156 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 716 studies in Carcinoma, Non-Small-Cell Lung with a site in Italy, or all of them as a file.
02

Study summary

Aim of the study is to evaluated the role of IGF1R and p95HER2 on prognosis in radically resected non small cell lung cancer patients

The primary objective is to correlate the expression of IGF1R and p95HER2 with survival.

03

Conditions studied

  • Non Small Cell Lung Cancer

Keywords

  • non small cell lung cancer patients
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Radically resected non small cell lung cancer patients

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Radically resected non small cell lung cancer patients with tumor tissue available

Exclusion criteria

Exclusion Criteria:

  • Tumor tissue not available
  • Clinical data not available
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
454 participants (actual)
Biospecimen retention
Samples with dna

Groups and cohorts

  • 1

    Radically resected Non small cell lung cancer patients in stage I-III

    Genetic: Protein expression by immunohistochemistry and immunofluorescence

Interventions

  • GeneticProtein expression by immunohistochemistry and immunofluorescence

    Protein expression by immunohistochemistry and immunofluorescence

06

What researchers measure

Primary outcomes

  1. Association of different biomarkers with survival

    Time frame: At the end of enrollment

Secondary outcomes

  1. Association of a specific biomarker with patient's characteristics

    Time frame: At the end of enrollment

07

Study locations

1 site
  • Istituto Clinco Humanitas
    Rozzano, Milan 20089, Italy
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2008
First posted
Oct 1, 2008
Start
Nov 2007
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Last update
Sep 10, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00763607
Lead sponsor
Armando Santoro, MD
Responsible party
Armando Santoro, MD (MD, Istituto Clinico Humanitas) — Sponsor-investigator
First posted
Oct 1, 2008
Start date
Nov 2007
Primary completion
Dec 2009
Completion
Dec 2009
Last update
Sep 10, 2022

Study contacts

Armando Santoro, MD
principal investigator · Istituto Clinico Humanitas

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion